miR-146a G>C基因多态性与中国原发性肝癌患者遗传易感性的Meta分析

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (7): 779-786.

miR-146a G>C基因多态性与中国原发性肝癌患者遗传易感性的Meta分析

李芸¹，李兵胜²，张卫芳¹，李义秀¹，李春¹，彭娟³，赖鑫⁴，朱静¹，徐睿来¹，熊爱珍¹

¹南昌大学第二附属医院药学部，南昌 330006，江西；²南昌市卫生学校药学教研室，南昌 330006，江西；³江西省人民医院药剂科，南昌 330006，江西；⁴南昌大学第一附属医院药学部，南昌 330006，江西

收稿日期:2016-10-20 修回日期:2017-04-21 出版日期:2017-07-26 发布日期:2017-07-19
通讯作者: 熊爱珍，女，硕士，主任药师，研究方向：临床药学。 Tel:0791-6296506 E-mail:xiongai@sina.com
作者简介:李芸，女，硕士，药师，研究方向：药物基因组学与个体化医学。 Tel：13755782764 E-mail:928055576@qq.com 李兵胜，共同第一作者，男，硕士，药师，研究方向：生物药剂学。 Tel:15579122703 E-mail:648941503@qq.com
基金资助:
江西省科技厅青年科学基金（20142BAB215035）

Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis

LI Yun ¹, LI Bingsheng ², ZHANG Weifang ¹, LI Yixiu ¹, LI Chun ¹, PENG Juan³, LAI Xin ⁴, ZHU Jing ¹, XU Ruilai¹, XIONG Aizhen ¹

¹Department of Pharmacy, the Second Affiliated Hospital to Nanchang University, Nanchang 330006, Jiangxi, China; ²The Health School of Nanchang, Nanchang 330006, Jiangxi，China; ³Department of Pharmacy, the People's Hospital in Jiangxi Province, Nanchang 330006, Jiangxi，China;⁴ Department of Pharmacy, the First Affiliated Hospital to Nanchang University, Nanchang 330006, Jiangxi，China

Received:2016-10-20 Revised:2017-04-21 Online:2017-07-26 Published:2017-07-19

摘要/Abstract

摘要：

目的: 对国内外公开发表的中国原发性肝癌与miR-146a G>C(rs2910164)遗传易感性的相关文献进行Meta分析。方法: 检索PubMed数据库、Cochrane Library数据库、中国学术期刊全文数据库(CNKI)和万方数据库获得文献。检索时限为自建库至2017年3月。采用Stata 12.0软件进行Meta分析，计算各基因型的合并比值比(OR)及95%置信区间(CI)。结果: 共纳入9篇病例对照研究，累计病例组3 937例，健康对照组5 025例，研究间存在中等强度的异质性。固定效应的合并OR值及95%CI在显性模型［(GG+GC)/CC］和隐性模型［GG/(GC+CC)］分别为1.26(1.12,1.41)(P=0.00)和1.23(1.12,1.34)(P=0.00)，随机效应等位模型(G/C)为1.17(1.10,1.25)(P=0.00)。Meta回归分析发现显性模型样本的地域来源与合并OR值正相关。亚组分析表明，在中东人群和西部人群及采用PCR-RFLP分型时，miR-146a G>C与原发性肝癌的遗传易感性密切相关；而在西南人群和采用非PCR-RFLP(Non-PCR-RFLP)分型时无明显相关性。三个基因型的敏感性分析结果稳定，也没有发表偏倚。结论: miR-146a G>C与原发性肝癌的遗传易感性密切相关，携带G等位的个体有更高的发病风险，该位点基因多态性具有成为原发性肝癌的生物标记物的潜能。

关键词: Meta分析, 原发性肝癌, miR-146a G>C

Abstract:

AIM:This Meta-analysis including only Chinese primary hepatocellular carcinoma (PHC) patients was conducted to assess the associations of miR-146a G>C(rs2910164) with PHC risk. METHODS: Literatures were researched using PubMed, Cochrane Library, Wanfang and China National Knowledge Infrastructure(CNKI) databases to identify relevant studies from the establishment of database to March 2017. Stata software (version 12.0) was used to check odds ratio (OR) and 95% confidence interval (CI). RESULTS: A total of nine published case studies were included in this Meta-analysis, which included 3 937 cases and 5 025 controls. The result suggested SNP was associated with PHC risk in dominant model ［(GG+GC)/CC］［1.26, (1.12-1.41), P=0.00］, recessive model［GG/(GC+CC)］［1.23,(1.12-1.34), P=0.00］and allele model(G/C)［1.17, (1.10-1.25), P=0.00］under random effect and fixed effect. Heterogeneity was found among and within studies. Meta regression indicated that the effect size was positively correlated with sample region in dominant model. Subgroup analysis revealed a significant association of this SNP with PHC risk among studies of people from middle-eastern and western area and people using PCR-RFLP, but no such association was found using Non-PCR-RFLP and in studies of people from southwestern area. Three genotypes presented stable sensitivity and absent publication bias. CONCLUSION: miR-146a G>C is associated with PHC risk in Chinese population, and G allelic increased the PHC risk, this SNP may be a biomarker for PHC occurrence.

Key words: Meta-analysis, primary hepatocellular carcinoma, miR-146a G>C

中图分类号:

R195.1

李芸，李兵胜，张卫芳，李义秀，李春，彭娟，赖鑫，朱静，徐睿来，熊爱珍. miR-146a G>C基因多态性与中国原发性肝癌患者遗传易感性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(7): 779-786.

LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen. Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.

参考文献

［1］Farazi PA, Depinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment［M］. Nat Rev Cancer， 2006，6(9):674-687.
［2］Jazdzewski K, Murray EL, Schoenberg DR,et al. Common SNP in Pre-miR-146a decreases mature miRNA expression and predisposes to papillary thyroid carcinoma［J］. Proc Natl Acad Sci U S A， 2008，105(20):7269-7274.
［3］麦艾. miR-146a异常表达及其单核苷酸多态位点rs2910164与胃癌易感性的相关研究［D］. 广州医科大学,2014.
［4］Hu Z, Liang J, Shen H,et al. Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in chinese women［J］.Hum Mutat，2009，30(1):79-84.
［5］Cong N, Chen H, Bu WZ,et al.MiR-146a G>C Polymorphisms and risk of hepatocellular carcinoma in a chinese population［J］. Tumour Biol，2014，35(6):5669-5673.
［6］Chen JJ, Cao XD,Zhang HY. miR-146a rs2910164 Polymorphism is associated with hepatocellular carcinoma: a meta-analysis［M］.Int J Clin ExP Med，2015，8(9):15852-15856.
［7］Chen M, Luo F, Yu J,et al. Common functional polymorphism within miR-146a and miR-196a-2 as susceptibility loci for hepatocellularcarcinoma: An updated Meta-analysis［M］. Meta Gene，2015， 7:40-47.
［8］Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer［J］. Cancer Chemother Pharmacol，2010，65(3):437-446.
［9］Harbord RM, Egger M, Sterne JA,et al.A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints［J］. Stat Med，2006，25(20):3443-3457.
［10］Qi JH, Wang J, Chen J, et al. High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in chinese patients［J］.BMC Cancer，2014，14:643.
［11］Zhou B, Dong LP, Zhao LF,et al.Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellularcarcinoma in a Chinese population［J］.Tumour Biol，2014 35(8):7775-7780.
［12］郝玉霞. miR196α基因多态性在原发性肝癌发生发展中的作用及机制研究［D］.山西医科大学, 2014.
［13］Kou JT, Fan H, He Q,et al. Association between four common microRNA polymorphisms and the risk of hepatocellular carcinoma and HBV infection［J］. Oncol Lett，2014，8(3):1255-1260.
［14］Shan YF, Huang YH, Zhang QY,et al. miR-499A>G rs3746444 and miR-146aG>C expression and hepatocellular carcinoma risk in the chinese population［J］. Genet Mol Res，2013，12(4):5365-5371.
［15］Li X, Li K, Wu Z.Association of four common SNPs in microRNA polymorphisms with the risk of hepatocellular carcinoma［J］. Int J Clin ExP Pathol，2015，8(8):9560-9566.
［16］Zhang J, Wang R, Liu J,et al. Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a chinese population［J］. Asian Pac J Cancer Prev，2013，14(11):6427-6431.
［17］Akkiz H, Bayram S, Sandokol M,et al.No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinomadevelopment in Turkish population:a case-control study［J］. Gene，2011，486(1-2):104-109.
［18］张新伟,潘善东,沈洪兵,等.微小RNA前体区域基因多态与肝细胞肝癌遗传易感性关联的研究［J］.中华预防医学杂志, 2011, 45(3):239-243.
［19］Zeng Y, Sun QM, Wang B,et al. Correlation between pre-miR-146a C/G polymorphism and gastric cancer risk in chinese population［J］. World J Gastroenterol，2010，16(28):3578-3583.
［20］李玉春.MicroRNA相关单核苷酸多态性与原发性肝癌遗传易感性研究［D］. .郑州大学,2012.
［21］王文章.miR-146a单核苷酸多态与肝癌遗传易感性的关联研究及肿瘤相关microRNA的微阵列分析的研究［D］.复旦大学,2011.
［22］黄琼华.miRNA-146a、miRNA-196a2基因多态性与广西壮族人群原发性肝癌的相关性研究［D］.广西医科大学,2013.
［23］Li D, Peng JJ, Zhang T,et al.Genetic variations in microRNA genes and susceptibility to hepatocellular carcinoma［J］. Genet Mol Res，2015，14(1):1926-1931.
［24］Xiang Y, Fan S, Zhang LP,et al.Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population［J］. Mol Biol ReP，2012，39(6):7019-7023.
［25］Xu T, Zhu Y, Zhuang SM,et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma［J］.Carcinogenesis， 2008，29(11):2126-2131.
［26］Zhou J, Lv R, Wang L,et al.Association between two genetic variants in miRNA and primary liver cancer risk in the chinese population［J］.DNA Cell Biol，2012，31(4):524-530.
［27］Yan P, Xia M, Gong L,et al.Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma［J］. Int J Clin ExP Pathol，2015，8(11):15177-15183.
［28］Guan DX, Shi J, Xie D,et al.Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates asubtype of hepatocellular carcinoma through TSC2-AKT cascade［J］. Hepatology，2015，62(6):1791-1803.
［29］Li J, Xu Y, Chen GQ,et al.Cbx4 governs HIF-1α to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity［J］. Cancer Cell，2014，25(1):118-131.
［30］Liepelt A, Tacke F. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases［J］. Am J Physiol Gastrointest Liver Physiol，2016，;311(2):G203-209.
［31］Su R, Nan H, Guo H,et al. Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognosticvalue of these biomarkers in hepatocellular carcinoma［J］. Hepatol Res，2016，46(13):1380-1391.
［32］Zhang Z, Zhang Y, Sun XX, et al. microRNA-146a inhibits cancer Metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma［J］. Mol Cancer， 2015，14:5.
［33］阮萃才.环境因素与肝癌［J］.上海环境科学,1986(5):35-40.
［34］Iakova P, Timchenko L, Timchenko NA. Intracellular signaling and hepatocellular carcinoma［J］.Semin Cancer Biol，2011，21(1):28-34.
［35］Teoh NC. Proliferative drive and liver carcinogenesis: too much of a good thing［J］? J Gastroenterol Hepatol， 2009 ，24(12):1817-1825.
［36］Sidhu K, Kapoor NR, Kumar V,et al. The "Macro" world of microRNAs in hepatocellular carcinoma［J］.Front Oncol，2015，5:68.
［37］黄宇,黄迪,古维立,等.非乙非丙型肝癌与HBV/HCV相关肝癌的临床特点及预后影响因素分析［J］.临床肝胆病杂志，2016.32(3): 514-517.
［38］Stickel N, Prinz G, Pfeifer D,et al.miR-146aregulates the TRAF6/TNF-axis in donor T cells during GVHD［J］.Blood，2014，124(16):2586-2595.
［39］Ramkaran P, Khan S, Phulukdaree A, et al.miR-146a polymorphism influences levels of miR-146a, IRAK-1, and TRAF-6 in young patients with coronary artery disease［J］.Cell Biochem Biophys，2014，68(2):259-266.

[1]	石丹丹, 孙祎尧, 陈晓琦, 杨芳明, 张传雷, 王新亭, 袁长威, 陈欣菊. 扶正消瘤颗粒治疗原发性肝癌的疗效观察及血清代谢组学分析[J]. 中国临床药理学与治疗学, 2023, 28(11): 1247-1262.
[2]	于朝雷, 柏建岭, 于浩, 赵杨. 基于R-Shiny实现临床试验信息检索及Meta分析的工具开发——以非小细胞肺癌为例[J]. 中国临床药理学与治疗学, 2020, 25(9): 984-991.
[3]	王高卿, 江伟, 华永飞. 雷替曲塞联合腹腔镜肝切除术对原发性肝癌患者肝功能及CIART、AFP-L3、GP73的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 752-756.
[4]	陈文君，阮邹荣，相小强. 生理药代动力学模型的发展应用动态及其与其他建模方法的融合[J]. 中国临床药理学与治疗学, 2020, 25(3): 299-305.
[5]	李禄金, 丁俊杰, 刘东阳, 王曦培, 邓晨辉, 季双敏, 陈文君, 马广立, 王鲲, 盛玉成, 许羚, 裴奇, 陈渊成, 陈锐, 史军, 李改玲, 王亚宁, 王玉珠, 谢海棠, 周田彦, 方翼, 张菁, 焦正, 胡蓓, 郑青山. 基于模型的荟萃分析一般考虑[J]. 中国临床药理学与治疗学, 2020, 25(11): 1250-1267.
[6]	赵鹏程，徐丽丽，李艳玲. 右美托咪定联合靶控输注丙泊酚在肝癌射频消融治疗中的临床效果[J]. 中国临床药理学与治疗学, 2018, 23(6): 682-687.
[7]	邵姚君，郑童，王艳秋，刘凌，姚应水. 尼莫地平联合氟桂利嗪对偏头痛的疗效及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2018, 23(6): 646-652.
[8]	王艳秋，金岳龙，姚应水，刘凌，朱丽君，常微微，陈燕，郑童，邵姚君. 门冬胰岛素与生物合成人胰岛素治疗妊娠期糖尿病Meta分析[J]. 中国临床药理学与治疗学, 2018, 23(5): 541-546.
[9]	王卫煜，于浩. 格雷类药物治疗冠心病疗效的网状Meta分析[J]. 中国临床药理学与治疗学, 2018, 23(3): 301-307.
[10]	袁刚，胡爱荣，胡耀仁，曾传莉，朱德东，石小军. 恩替卡韦和阿德福韦酯治疗代偿期乙肝肝硬化临床疗效及远期预后[J]. 中国临床药理学与治疗学, 2018, 23(2): 170-174.
[11]	伍嘉琪，杨俏雯，陈秀敏，黄闰月，黄清春，赵越，吴晓东. 艾拉莫德联合甲氨蝶呤治疗类风湿关节炎有效性和安全性的系统评价和Meta分析[J]. 中国临床药理学与治疗学, 2018, 23(10): 1132-1140.
[12]	何扬彪，袁春樱，史国军. 膈下逐瘀汤对瘀血内结型肝癌术后血凝状态与生存质量的影响[J]. 中国临床药理学与治疗学, 2017, 22(9): 1056-1061.
[13]	张晓宇，方正美，姚应水. 瘦素及其受体基因多态性与高血压相关性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(8): 910-916.
[14]	容国义，王淑美，唐末. 中医化痰法治疗非小细胞肺癌疗效的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(7): 787-794.
[15]	伍长娟，汤天生. 振源胶囊辅助治疗慢性心力衰竭疗效及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(3): 299-304.